SCHEMBL5526288

SCHEMBL5526288

COc1cc(OC)cc(/C(N)=N\O)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.50
RECQL P46063 1/20 0.50
ALDH1A1 P00352 2/20 0.48
KDM4E B2RXH2 2/20 0.45
MAPT P10636 2/20 0.45
LMNA P02545 2/20 0.43
GFER P55789 1/20 0.43
KMT2A Q03164 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
RAB9A P51151 4/20 0.43
NPC1 O15118 3/20 0.43
ATM Q13315 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.42
PDE4A P27815 4/20 0.42
PDE4B Q07343 4/20 0.42
PDE4C Q08493 4/20 0.42
PDE4D Q08499 4/20 0.42
PARP1 P09874 1/20 0.41
PRSS1 P07477 1/20 0.41
PRSS2 P07478 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2698398 1.00 GAA (0.50) GAARECQLALDH1A1KDM4EMAPT
SCHEMBL2698400 1.00 GAA (0.50) GAARECQLALDH1A1KDM4EMAPT
SCHEMBL5224043 0.88 GAA (0.41) GAARECQLALDH1A1KDM4EMAPT
SCHEMBL5224959 0.87 GAA (0.44) GAARECQLALDH1A1KDM4EMAPT
SCHEMBL14738759 0.85 RXRA (0.45) GAARECQLKDM4EMAPTLMNA
SCHEMBL14738760 0.85 RXRA (0.45) GAARECQLKDM4EMAPTLMNA
SCHEMBL6976229 0.85 RXRA (0.45) GAARECQLKDM4EMAPTLMNA
SCHEMBL20963871 0.84 KDM4E (0.48) GAARECQLALDH1A1KDM4EMAPT
SCHEMBL30614536 0.84 KDM4E (0.48) GAARECQLALDH1A1KDM4EMAPT
SCHEMBL29278609 0.84 KDM4E (0.48) GAARECQLALDH1A1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8519149-B2 Tricyclic compounds as mPGES-1 inhibitors GLENMARK PHARMACEUTICALS S.A. (CH) 2013-08-27 US disclosed
US-8519149-B2 Tricyclic compounds as mPGES-1 inhibitors GLENMARK PHARMACEUTICALS S.A. (CH) 2013-08-27 US disclosed
US-20120108583-A1 Tricyclic Compounds As mPGES-1 Inhibitors GLENMARK PHARMACEUTICALS S.A. (CH) 2012-05-03 US disclosed
US-20120108583-A1 Tricyclic Compounds As mPGES-1 Inhibitors GLENMARK PHARMACEUTICALS S.A. (CH) 2012-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120108583-A1 Tricyclic Compounds As mPGES-1 Inhibitors PTGES, PTGS1, PTGIS GAA 1542/4885RECQL 2931/4885ALDH1A1 263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.